carbapenems has been researched along with fosfomycin in 62 studies
Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (fosfomycin) | Trials (fosfomycin) | Recent Studies (post-2010) (fosfomycin) |
---|---|---|---|---|---|
7,355 | 147 | 5,277 | 2,335 | 181 | 1,022 |
Protein | Taxonomy | carbapenems (IC50) | fosfomycin (IC50) |
---|---|---|---|
UDP-N-acetylglucosamine 1-carboxyvinyltransferase | Escherichia coli K-12 | 3.5795 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (1.61) | 29.6817 |
2010's | 35 (56.45) | 24.3611 |
2020's | 26 (41.94) | 2.80 |
Authors | Studies |
---|---|
Chalevelakis, G; Damala, M; Falagas, ME; Michalopoulos, A; Rafailidis, P; Virtzili, S | 1 |
Giamarellou, H; Poulakou, G | 1 |
Kiratisin, P; Leelaporn, A; Leelarasmee, A; Netikul, T | 1 |
Apisarnthanarak, A; Mundy, LM | 2 |
Arda, B; Pullukcu, H; Senol, S; Sipahi, H; Sipahi, OR; Tasbakan, M; Ulusoy, S; Yamazhan, T | 1 |
Ahmed-Bentley, J; Peirano, G; Pitout, JD; Woodford, N | 1 |
Chayakul, P; Garey, KW; Pattharachayakul, S; Santimaleeworagun, W; Tansakul, P; Wongpoowarak, P | 1 |
Hall, GS; Neuner, EA; Sekeres, J; van Duin, D | 1 |
Bachmann, A; Bonkat, G; Braissant, O; Frei, R; Gasser, TC; Müller, G; Rieken, M; Tschudin-Suter, S; Widmer, AF; Wyler, S | 1 |
Giannella, M; Lewis, R; Petrosillo, N; Viale, P | 1 |
Hernández, E; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
Burgmann, H; Lingscheid, T; Mitteregger, D; Poeppl, W; Tobudic, S | 1 |
Abreu-Lanfranco, O; Bheemreddy, S; Dhar, S; Hayakawa, K; Kaye, KS; Lephart, PR; Marchaim, D; Martin, ET; Mynatt, RP; Pogue, JM; Sunkara, B; Zhao, JJ | 1 |
Colon-Urban, R; Kopacz, J; Mariano, N; Segal-Maurer, S; Sychangco, P; Urban, C; Wehbeh, W | 1 |
Anders, A; Gatermann, SG; Kaase, M; Szabados, F | 1 |
Feng, X; Fu, Y; Li, Y; Liu, HM; Qi, H; Qin, S; Rong, L; Shan, L; Tian, H; Wen, JG; Xu, H; Xu, L; Yu, Y; Zeng, L; Zhang, Q | 1 |
Sirijatuphat, R; Thamlikitkul, V | 1 |
Abbasi, SA; Day, KM; Paterson, DL; Perry, JD; Raza, MW; Sartor, AL; Sidjabat, HE | 1 |
Chomnawang, MT; Khuntayaporn, P; Kunakonvichaya, B; Montakantikul, P; Thirapanmethee, K | 1 |
Cai, Y; Di, X; Liang, B; Liu, B; Liu, Y; Ni, W; Wang, J; Wang, R; Zhang, X | 1 |
Amaya-Villar, R; Díaz-Martín, A; Ferrándiz-Millón, C; Garnacho-Montero, J; Gutiérrez-Pizarraya, A; López-Sánchez, JM | 1 |
Gil-Romero, Y; Gómez-Garcés, JL; Muñoz-Paraíso, C; Regodón-Domínguez, M; Sanz-Rodríguez, N | 1 |
Asuphon, O; Houngsaitong, J; Kiratisin, P; Montakantikul, P; Sonthisombat, P | 1 |
Al-Abri, SS; Al-Jardani, A; Aldeesi, Z; Carattoli, A; Darwish, D; Ghazawi, A; Hashmey, R; Jamal, W; Pál, T; Rotimi, V; Sonnevend, Á; Villa, L | 1 |
Carrilho, C; Costa, SF; Guimaraes, T; Levin, AS; Marchi, AP; Miranda, L; Rizek, C; Rosa, JF | 1 |
Hu, YY; Huang, L; Zhang, R | 1 |
Abbo, LM; Aragon, L; Bonomo, RA; Camargo, JF; Hujer, AM; Martinez, O; Nicolau, DP; Perez, F; Perez-Cardona, A; Rojas, LJ; Rosa, R; Rudin, SD; Tekin, A | 1 |
Abbo, LM; Bonomo, RA; Camargo, JF; Hujer, AM; Martinez, O; Perez, F; Perez-Cardona, A; Rojas, LJ; Rosa, R; Rudin, SD | 1 |
Chatsuwan, T; Singkham-In, U | 1 |
Cao, Y; He, L; Hu, F; Wang, A; Wang, C; Yin, D; Zhang, L | 1 |
Chakraborty, T; Fritzenwanker, M; Herold, S; Imirzalioglu, C; Wagenlehner, FM; Zimmer, KP | 1 |
Bodmann, KF | 1 |
Avery, LM; Nicolau, DP; Sutherland, CA | 1 |
Dewar, JB; Ekwanzala, MD; Kamika, I; Momba, MNB | 1 |
Link, I; Loose, M; Naber, KG; Wagenlehner, FME | 1 |
Akinci, E; Baran, I; Bodur, H; Mumcuoglu, I; Sertcelik, A | 1 |
Ahn, JY; Choi, H; Choi, JY; Choi, YH; Jeong, SJ; Kim, JM; Ku, NS; Lee, SH; Lim, YS; Shin, SJ; Song, YG; Yeom, JS; Yong, D | 1 |
Chen, S; Li, XY; Liu, CX; Liu, P; Qi, M; Wu, ZY | 1 |
Carone, G; Dalfino, L; De Robertis, A; Del Prete, R; Mosca, A; Romanelli, F; Stufano, M | 1 |
Cao, J; Dhanasekaran, V; Fang, R; Li, J; Lithgow, T; Liu, H; Perlaza-Jiménez, L; Tian, X; Wang, C; Wang, Q; Zhao, Y; Zheng, X; Zhou, T | 1 |
Ayfan, AK; Mohd Sazlly Lim, S; Naicker, S; Roberts, JA; Sime, FB; Zowawi, H | 1 |
Ashraf, T; Barathan, G; Darwish, D; Ghazawi, A; Hashmey, R; Pál, T; Rizvi, TA; Sonnevend, Á | 1 |
Deemer, K; Fronczek, C; Grey, J; Marr, K | 1 |
Chusri, S; Ontong, JC; Ozioma, NF; Voravuthikunchai, SP | 1 |
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E | 1 |
Akalın, H; Eser, ÖK; Gürpınar, Ö; Köksal, İ; Otlu, B; Özakın, C; Ünal, S; Zarakolu, P | 1 |
Ambretti, S; Antonelli, A; Bartoletti, M; Bassetti, M; Bussini, L; Cavallo, R; Coppi, M; Corcione, S; De Rosa, FG; Dettori, S; Gaibani, P; Giacobbe, DR; Giani, T; Giannella, M; Lewis, R; Marchese, A; Marconi, L; Pascale, R; Rossolini, GM; Shbaklo, N; Viale, P | 1 |
Chen, L; Chen, T; Fang, R; Liao, W; Xu, C; Zhang, S; Zhou, C; Zhou, T | 1 |
Courtois, R; Danneels, P; Dubée, V; Eveillard, M; Kempf, M; Mahieu, R; Quinqueneau, C; Rihet, C; Vannier, C | 1 |
Li, M; Liu, Y; Ma, W; Sun, L; Sun, S; Wu, J; Zhao, W | 1 |
Guery, B; Jacot, D; Papadimitriou-Olivgeris, M | 1 |
Aysert-Yildiz, P; Dizbay, M; Habibi, H; Özgen-Top, Ö | 1 |
Crudele, V; De Filippis, A; Della Rocca, MT; Finamore, E; Foglia, F; Franci, G; Galdiero, M; Greco, G | 1 |
Afridi, FI; Baig, S; Jamal, Q; Khan, R; Sani, AI; Zaidi, SAA | 1 |
Borrazzo, C; Bruni, A; Garofalo, E; Gullì, S; Lionello, R; Longhini, F; Marascio, N; Matera, G; Quirino, A; Romeo, F; Russo, A; Serapide, F; Serraino, R; Torti, C; Trecarichi, EM | 1 |
Adaleti, R; Aksaray, S; Arıcı, N; Çalık, Ş; Kansak, N; Nakipoğlu, Y; Şenbayrak, S | 1 |
Fukasawa, T; Kawakami, K; Okura, T; Takahashi, H; Urushihara, H | 1 |
Birinci, A; Ertokatlı, M; Güney, DB; Hacıeminoğlu Ülker, K; Karacan Temür, G; Tanrıverdi Çaycı, Y | 1 |
Aygen, B; Bolat, D; Dinc, G; Eren, EE; Gönen, ZB; İzci, F; Ture, Z; Ünüvar, GK; Yay, AH; Yıldız, O | 1 |
Akalın, H; Girgin, NK; İşçimen, R; Kahveci, FŞ; Kaya, PK; Önal, U; Özakın, C; Tüzemen, NÜ | 1 |
Baum, K; Bonomo, RA; Doi, Y; Evans, SR; Fowler, VG; Hamasaki, T; Komarow, L; Lodise, TP; Patel, R; Rodvold, KA; Rouphael, N; Satlin, MJ; Schwager, N; Souli, M; Tamma, PD; van Duin, D; Van Tyne, D | 1 |
5 review(s) available for carbapenems and fosfomycin
Article | Year |
---|---|
Multidrug-resistant Gram-negative infections: what are the treatment options?
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Minocycline; Polymyxins; Tigecycline | 2009 |
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Colistin; Drug Therapy, Combination; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Minocycline; Rifampin; Risk Factors; Tigecycline | 2013 |
Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Carbapenems; Colistin; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Humans; Microbial Sensitivity Tests; Minocycline; Polymyxins; Sulbactam; Tigecycline | 2015 |
Treatment Options for Carbapenem- Resistant Gram-Negative Infections.
Topics: Aminoglycosides; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Therapy, Combination; Escherichia coli; Fluoroquinolones; Fosfomycin; Germany; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Piperacillin; Pseudomonas aeruginosa; Tigecycline | 2018 |
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin | 2021 |
2 trial(s) available for carbapenems and fosfomycin
Article | Year |
---|---|
Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Critical Illness; Cross Infection; Female; Fosfomycin; Humans; Infusions, Intravenous; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2010 |
Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Fosfomycin; Humans; Male; Microbial Sensitivity Tests; Pilot Projects; Treatment Outcome | 2014 |
55 other study(ies) available for carbapenems and fosfomycin
Article | Year |
---|---|
In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Drug Synergism; Escherichia coli; Escherichia coli Infections; Fosfomycin; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2010 |
Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia.
Topics: Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Doripenem; Drug Therapy, Combination; Female; Fosfomycin; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa | 2010 |
Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fosfomycin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Urinary Tract Infections; Young Adult | 2010 |
New Delhi metallo-beta-lactamase from traveler returning to Canada.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Canada; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; India; Male; Microbial Sensitivity Tests; Prostatitis; Pyelonephritis; Travel; Urine | 2011 |
Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.
Topics: Carbapenems; Colistin; Cross Infection; Doripenem; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fosfomycin; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Retrospective Studies; Time Factors | 2012 |
In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Colistin; Drug Therapy, Combination; Fosfomycin; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymerase Chain Reaction; Thailand; Time Factors | 2011 |
Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterococcus faecium; Female; Fosfomycin; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Retrospective Studies; Treatment Outcome; Urinary Tract Infections | 2012 |
Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ciprofloxacin; Contraindications; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fosfomycin; Humans; Male; Middle Aged; Nitrofurantoin; Prevalence; Retrospective Studies; Treatment Failure; Treatment Outcome; Urinary Tract; Urinary Tract Infections; Young Adult | 2013 |
[Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; Microbial Sensitivity Tests; Prevalence; Urinary Tract Infections; Urine | 2013 |
In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Resistance, Multiple, Bacterial; Fosfomycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 2013 |
Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Enterococcus; Fosfomycin; Gram-Positive Bacterial Infections; Humans; Michigan; Microbial Sensitivity Tests; Urinary Tract Infections; Vancomycin Resistance | 2013 |
Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Fosfomycin; Humans; Klebsiella pneumoniae; Minocycline; Tigecycline; Urinary Tract | 2013 |
Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany.
Topics: beta-Lactam Resistance; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Fosfomycin; Germany; Humans; Microbial Sensitivity Tests | 2014 |
High incidence and endemic spread of NDM-1-positive Enterobacteriaceae in Henan Province, China.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; China; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Epidemiological Monitoring; Fosfomycin; Genotype; Humans; Incidence; Multilocus Sequence Typing; Plasmids | 2014 |
Molecular epidemiology of NDM-1-producing Enterobacteriaceae and Acinetobacter baumannii isolates from Pakistan.
Topics: Acinetobacter baumannii; Amdinocillin; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; DNA, Bacterial; Doripenem; Enterobacteriaceae; Fosfomycin; Humans; Meropenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Pakistan; Thienamycins | 2014 |
Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Drug Synergism; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; China; Colistin; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
[In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2016 |
Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
Topics: Anti-Bacterial Agents; Carbapenems; Critical Illness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fosfomycin; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thailand | 2016 |
Characterization of NDM-7 Carbapenemase-Producing Escherichia coli Isolates in the Arabian Peninsula.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clone Cells; Colistin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fosfomycin; Gene Expression; Humans; Kuwait; Microbial Sensitivity Tests; Minocycline; Multilocus Sequence Typing; Oman; Phylogeny; Plasmids; Saudi Arabia; Tigecycline; United Arab Emirates | 2017 |
Clonality, outer-membrane proteins profile and efflux pump in KPC- producing Enterobacter sp. in Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Brazil; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterobacter; Enterobacteriaceae Infections; Female; Fosfomycin; Genes, Bacterial; Hospitals; Humans; Male; Membrane Proteins; Microbial Sensitivity Tests; Middle Aged; Minocycline; Polymerase Chain Reaction; Polymyxin B; Tigecycline; Young Adult | 2017 |
Prevalence of fosfomycin resistance and plasmid-mediated fosfomycin-modifying enzymes among carbapenem-resistant Enterobacteriaceae in Zhejiang, China.
Topics: Carbapenems; China; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Proteins; Fosfomycin; Gene Transfer, Horizontal; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids | 2017 |
Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug-Resistant Klebsiella pneumoniae in a Multivisceral Transplant Patient.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Female; Fosfomycin; Humans; Intestines; Kidney Transplantation; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Postoperative Complications; Precision Medicine | 2017 |
"Double carbapenem" and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Fosfomycin; Humans; Kidney Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Treatment Outcome; Urinary Tract Infections | 2018 |
In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Colistin; Fosfomycin; Humans; Microbial Sensitivity Tests; Thailand | 2018 |
Clinical and molecular epidemiologic characteristics of carbapenem-resistant Klebsiella pneumoniae infection/colonization among neonates in China.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carrier State; China; Drug Therapy, Combination; Female; Fosfomycin; Hospitals, Pediatric; Humans; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Retrospective Studies; Treatment Outcome | 2018 |
Oral Fosfomycin-Supplemental Information Necessary.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Fosfomycin; Humans | 2019 |
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States | 2019 |
Genome sequence of carbapenem-resistant Citrobacter koseri carrying bla
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Citrobacter koseri; Drug Resistance, Multiple, Bacterial; Fosfomycin; Genome Size; Genome, Bacterial; High-Throughput Nucleotide Sequencing; Microbial Sensitivity Tests; Phylogeny; Plasmids; Sewage; Whole Genome Sequencing | 2020 |
Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Resistance, Multiple, Bacterial; Ertapenem; Fosfomycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Rifampin; Urinary Tract Infections | 2019 |
Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteriological Techniques; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Minocycline; Sulbactam; Vancomycin | 2020 |
In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Fosfomycin; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Minocycline; Pneumonia; Tigecycline | 2019 |
Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Carbapenems; China; Drug Resistance, Bacterial; Fosfomycin; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2020 |
In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2020 |
First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fosfomycin; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Phylogeny; Plasmids; Virulence Factors; Whole Genome Sequencing | 2020 |
Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Humans; Meropenem; Microbial Sensitivity Tests; Polymyxins; Sulbactam | 2020 |
In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Bacterial; Fosfomycin; Humans; Microbial Sensitivity Tests; Middle East; Tigecycline | 2020 |
Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cohort Studies; Escherichia coli; Escherichia coli Infections; Female; Florida; Fosfomycin; Humans; Male; Microbial Sensitivity Tests; Pharmacy Service, Hospital; Retrospective Studies; Urinary Tract Infections | 2020 |
Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fluoroquinolones; Fosfomycin; Klebsiella pneumoniae; Piperacillin; Tetracyclines | 2021 |
In-vitro activity of fosfomycin against
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales.
Topics: Agar; Aged; Anti-Bacterial Agents; Carbapenems; Colistin; Female; Fosfomycin; Gentamicins; Humans; Male; Microbial Sensitivity Tests; Retrospective Studies; Tigecycline | 2022 |
In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Escherichia coli; Fosfomycin; Humans; Imipenem; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Cefoxitin-based combination for ESBL-producing Enterobacteriaceae endocarditis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefoxitin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Endocarditis; Enterobacteriaceae; Escherichia coli; Escherichia coli Infections; Fosfomycin; Humans; Microbial Sensitivity Tests; Urinary Tract Infections | 2022 |
Antibacterial and antibiofilm activities of fosfomycin combined with rifampin against carbapenem-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Biofilms; Carbapenems; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin | 2022 |
How to Manage Pseudomonas aeruginosa Infections.
Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Pneumonia; Urinary Tract Infections | 2023 |
Antimicrobial resistance changing trends of Klebsiella pneumoniae isolated over the last 5 years.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2022 |
Increasing Frequency of New Delhi Metallo-beta-Lactamase and Klebsiella pneumoniae Carbapenemase Resistant Genes in a Set of Population of Karachi.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Colistin; Escherichia coli; Female; Fosfomycin; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Tigecycline | 2023 |
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Colistin; COVID-19; Fosfomycin; Humans; Pneumonia, Ventilator-Associated | 2023 |
Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Polymyxin B | 2023 |
Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated With Antibiotic Use: A Case-Crossover Study.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cross-Over Studies; Fosfomycin; Glycopeptides; Humans; Stevens-Johnson Syndrome; Trimethoprim, Sulfamethoxazole Drug Combination | 2023 |
[Investigation of O25b-ST131 Clone Frequency and Presence of Carbapenem and Fosfomycin Resistance Genes in Escherichia coli Isolates: First Detection of fosA3 from Escherichia coli O25bSTf131 Clone from Türkiye].
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clone Cells; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Fosfomycin; Humans; Microbial Sensitivity Tests | 2023 |
The efficacy of mesenchymal stem cell treatment and colistin-fosfomycin combination on colistin-resistant Acinetobacter baumannii sepsis model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Carbapenems; Colistin; Fosfomycin; Interleukin-6; Mesenchymal Stem Cells; Mice; Microbial Sensitivity Tests; Sepsis | 2023 |
Evaluation of the combination treatments with intravenous fosfomycin for carbapenem-resistant Klebsiella pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Fosfomycin; Humans; Klebsiella Infections; Klebsiella pneumoniae; Pneumonia, Ventilator-Associated; Retrospective Studies; Sepsis | 2023 |
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Leadership; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2023 |